Hibbett Statistics
Total Valuation
Pharma Mar has a market cap or net worth of 1.62 billion. The enterprise value is 1.53 billion.
| Market Cap | 1.62B |
| Enterprise Value | 1.53B |
Important Dates
The last earnings date was Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 17.57M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 12.74M |
Valuation Ratios
The trailing PE ratio is 32.79 and the forward PE ratio is 19.92.
| PE Ratio | 32.79 |
| Forward PE | 19.92 |
| PS Ratio | 7.28 |
| PB Ratio | 6.84 |
| P/TBV Ratio | 6.87 |
| P/FCF Ratio | 775.64 |
| P/OCF Ratio | 156.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.41, with an EV/FCF ratio of 732.72.
| EV / Earnings | 30.98 |
| EV / Sales | 6.92 |
| EV / EBITDA | 34.41 |
| EV / EBIT | 41.64 |
| EV / FCF | 732.72 |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.84 |
| Quick Ratio | 2.14 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 28.94 |
| Interest Coverage | 7.69 |
Financial Efficiency
Return on equity (ROE) is 21.94% and return on invested capital (ROIC) is 8.30%.
| Return on Equity (ROE) | 21.94% |
| Return on Assets (ROA) | 5.91% |
| Return on Invested Capital (ROIC) | 8.30% |
| Return on Capital Employed (ROCE) | 12.07% |
| Revenue Per Employee | 444,550 |
| Profits Per Employee | 98,671 |
| Employee Count | 500 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 0.19 |
Taxes
| Income Tax | -10.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +166.26% in the last 52 weeks. The beta is -0.11, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +166.26% |
| 50-Day Moving Average | 95.19 |
| 200-Day Moving Average | 88.57 |
| Relative Strength Index (RSI) | 37.35 |
| Average Volume (20 Days) | 1,140 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of 222.27 million and earned 49.34 million in profits.
| Revenue | 222.27M |
| Gross Profit | 211.11M |
| Operating Income | 36.92M |
| Pretax Income | 38.61M |
| Net Income | 49.34M |
| EBITDA | 42.19M |
| EBIT | 36.92M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 150.42 million in cash and 60.36 million in debt, giving a net cash position of 90.05 million.
| Cash & Cash Equivalents | 150.42M |
| Total Debt | 60.36M |
| Net Cash | 90.05M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 236.68M |
| Book Value Per Share | n/a |
| Working Capital | 189.81M |
Cash Flow
In the last 12 months, operating cash flow was 10.33 million and capital expenditures -8.25 million, giving a free cash flow of 2.09 million.
| Operating Cash Flow | 10.33M |
| Capital Expenditures | -8.25M |
| Free Cash Flow | 2.09M |
| FCF Per Share | n/a |
Margins
Gross margin is 94.98%, with operating and profit margins of 16.61% and 22.20%.
| Gross Margin | 94.98% |
| Operating Margin | 16.61% |
| Pretax Margin | 17.37% |
| Profit Margin | 22.20% |
| EBITDA Margin | 18.98% |
| EBIT Margin | 16.61% |
| FCF Margin | 0.94% |
Dividends & Yields
Pharma Mar does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 33.20% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.05% |
| FCF Yield | 0.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharma Mar has an Altman Z-Score of 7.13 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.13 |
| Piotroski F-Score | 6 |